BMS and Exelixis make headway against Novartis in kidney cancer

But the Swiss pharma giant is still defending its cancer med Afinitor.

By Nicole Gray • July 23, 2015

The FDA wants to figure out DTC ad claims' effect on consumers

The FDA wants to know whether or not DTC drug ads actually change viewers' perceptions about medications.

By Nicole Gray • July 23, 2015

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Tekmira to become Arbutus, shift focus to hep B

After Tekmira's merger with OnCore in March, the combined entity now boasts that largest hepatitis B (HBV) pipeline in the industry. 

By Nicole Gray • July 21, 2015

WHO prequalifies Novartis' Coartem for malaria

The newest formulation of Coartem is the first and only high strength ACT antimalarial treatment available for large-scale public use. 

By Nicole Gray • July 20, 2015

Innovation vs. access: The big drug battle in Trans-Pacific Partnership negotiations

The generics industry worries over the intellectual property provisions of the complex trade agreement.

By Nicole Gray • July 17, 2015

ASCO scorecard upgrades rating for Lilly's Alimta

Alimta (pemetrexed) fell short on an initial scorecard, but its score improved when ratings were focused on a more specific form of lung cancer.

By Nicole Gray • July 16, 2015

Allergan faces lost sales as Namenda generics hit market

The drug giant is anticipating a $200 million loss in forecasted sales.

By Nicole Gray • July 16, 2015

NHS Scotland approves funding for five new drugs

Patients in Scotland now have access to newly covered drugs for thyroid cancer, pulmonary arterial hypertension, Crohn's disaease and other conditions -- but Lyparza, used to treat ovarian cancer, was rejected for funding.

By Nicole Gray • July 15, 2015

Study: Off-label use of antipsychotics growing in teens/young adults

A study published in JAMA Psychiatry reveals that 4.63 million antipsychotic prescriptions for written for teens and young adults in 2010. 

By Nicole Gray • July 12, 2015

What Glaxo's strategy guru thinks the future holds for HIV markets

David Redfern said that eventually the only improvement left to make in treating HIV will be finding a permanent cure.

By Nicole Gray • July 10, 2015

Senior congressman joins chorus calling for heroin antidote price cut

Representative Elijah Cummings wrote to Governor Larry Hogan (R) to request that he cut a deal with Amphastar, which manufactures naloxone. 

By Nicole Gray • July 9, 2015

Pharma's newest adversaries on CME funding are... Hotel workers?

A 270,000-person strong hotel worker's union is fighting to end what it calls "out-of-control" CME payments by the pharma industry.

By Nicole Gray • July 7, 2015

Pharma flings accusations, dire predictions in wake of Greek financial crisis

Some say that a 'Grexit' would severely impact access to medications and their prices, while others are accusing pharma of twisting a crisis to shield its bottom line. 

By Nicole Gray • July 7, 2015

Big deal for biosims? Major French hospital group opts for Hospira's Remicade copy

Assistance Publique-Hôspitaux de Paris (AP-HP) is buying an infliximab biosimilar from the firm, which was acquired by Pfizer earlier this year, to treat its patients.    

By Nicole Gray • July 6, 2015

Drug makers warn EU over troubled Greece: Medicine supply 'may be in jeopardy'

The industry is warning that the Greek drug-supply chain may be severely disrupted if Greece leaves the Euro zone. 

By Nicole Gray • July 2, 2015

New study: Glaxo flu vax linked to increased narcolepsy risk

That's according to a study by Stanford researchers.

By Nicole Gray • July 2, 2015

Novo to halt Tresiba sales in Germany over pricing conflict

It's particularly striking given the size of the German market.

By Nicole Gray • July 2, 2015

'Innovation' is everywhere in biopharma—but what does that actually mean?

Innovation has many definitions. But it can’t exist without collaborative partnerships.

By Nicole Gray • July 2, 2015

Sanofi/MannKind might be facing a major flop with Afrezza inhaled insulin

Executives from the companies have been urging patience and promising better results down the line. But so far, the numbers are pretty bleak. 

By Nicole Gray • July 1, 2015

How Novartis' CEO wants to tackle an ever-aging world

Joe Jimenez spoke to McKinsey about his company's focus on serving the needs of an aging population.

By Nicole Gray • June 26, 2015

Bristol-Myers calls it quits on any new virology R&D programs

But the company's ongoing programs in virology will remain in place. 

By Nicole Gray • June 26, 2015

Report: It pays big to focus on diabetes drugs

According to a report from GlobalData, the diabetes medications market grew 5.1% in 2014.

By Nicole Gray • June 25, 2015

The early winners and losers in ASCO's highly anticipated cancer drug scorecard

ASCO's drug scorecard is designed to simplify therapeutic decision-making by comparing survival data for different regimens with costs and side effects. 

By Nicole Gray • June 24, 2015

Pay attention: Adults now main ADHD treatment target

That's according to the CEO of Shire. And he would know.

By Nicole Gray • June 23, 2015

More than 1,000 online drug sites under FDA scrutiny

FDA inspectors, along with other authorities, seized illegal drugs and medical devices received through post offices in Chicago, Miami, and New York. 

By Nicole Gray • June 19, 2015